4.90
0.20 (4.26%)
| Previous Close | 4.70 |
| Open | 4.80 |
| Volume | 3,599 |
| Avg. Volume (3M) | 18,676 |
| Market Cap | 48,470,704 |
| Price / Earnings (TTM) | 30.63 |
| Price / Book | 81.97 |
| 52 Weeks Range | |
| Earnings Date | 20 Mar 2025 - 24 Mar 2025 |
| Operating Margin (TTM) | 39,635.71% |
| Diluted EPS (TTM) | -1.51 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Quarterly Earnings Growth (YOY) | -19.50% |
| Total Debt/Equity (MRQ) | 52.76% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | -17.14 M |
| Levered Free Cash Flow (TTM) | -11.27 M |
| Return on Assets (TTM) | -135.80% |
| Return on Equity (TTM) | -485.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Serina Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 61.81% |
| % Held by Institutions | 3.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Broadwood Capital Inc | 31 Dec 2024 | 85,219 |
| Waverly Advisors, Llc | 31 Dec 2024 | 67,492 |
| Keel Point, Llc | 31 Dec 2024 | 17,774 |
| Piscataqua Savings Bank | 31 Dec 2024 | 28 |
| Riggs Asset Managment Co. Inc. | 31 Dec 2024 | 24 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Apr 2025 | Announcement | Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference |
| 24 Mar 2025 | Announcement | Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting |
| 24 Mar 2025 | Announcement | Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights |
| 12 Feb 2025 | Announcement | Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors |
| 03 Feb 2025 | Announcement | Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients |
| 15 Jan 2025 | Announcement | Serina Therapeutics Announces Sale of UniverXome Subsidiary |
| 14 Jan 2025 | Announcement | Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |